AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31721914
Drug: Antibiotic in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic in the diet (0.01 g kg‐1)
Trial: 31721914
Drug: Antibiotic in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic in the water (0.002 g L‐1)
Trial: 31721914
Drug: Commercial probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial probiotic (Saccharomyces cerevisiae) in the diet (1 g Kg‐1)
Trial: 31721914
Drug: Antibiotic in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic in the water and yeast in the diet (0.002 g L‐1 and 1 g Kg‐1)
Trial: 31721914
Drug: Yeast in
RxNorm normalized name: Bakers Yeast Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yeast in the diet (1 g Kg‐1)
Trial: 24923259
Drug: ACT (Acceptance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT (Acceptance and Commitment Therapy)
Trial: 19108951
Drug: MDT (Multidisciplinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDT (Multidisciplinary Treatment)
Trial: 16574123
Drug: Peripheral intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral intravenous cannulas re‐sited only when complications occurred
Trial: 16574123
Drug: Peripheral intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral intravenous cannulas re‐sited every 3 days
Trial: 15475527
Drug: Dichloroacetate (DCA)
RxNorm normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dichloroacetate (DCA) infusion during rhythmic handgrip (RHG) exercise
Trial: 15881488
Drug: Pioglitazone plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone plus metformin
Trial: 2404805
Drug: Gestrinone 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gestrinone 1.25 mg twice weekly (group I)
Trial: 2404805
Drug: Gestrinone 2.5
RxNorm normalized name: gestrinone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gestrinone 2.5 mg twice weekly (group II)
Trial: 2404805
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of gestrinone
Trial: 30570303
Drug: Dissonance-based Body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dissonance-based Body Project treatment (BPT)
Trial: 30570303
Drug: Supportive mindfulness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive mindfulness treatment
Trial: 28265678
Drug: Anakinra 100
RxNorm normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra 100 mg daily for 4 weeks
Trial: 19179916
Drug: Daily walks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily walks
Trial: 11852293
Drug: Theophylline (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (10-20 microg/mL after 15 days of treatment)
Trial: 31502676
Drug: Original method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original method for generating null distributions of statistics pertaining to differences in G matrices
Trial: 31502676
Drug: Modified method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified method for generating null distributions of statistics pertaining to differences in G matrices
Trial: 26362226
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and vitamin D supplementation (800 mg calcium and 400 IU vitamin D daily for 6 months)
Trial: 23680679
Drug: 8-week, twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-week, twice weekly exercise program
Trial: 15854942
Drug: Preoperative methylene
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative methylene blue administration (2 mg/kg intravenously for more than 30 minutes, starting 1 hour before surgery)
Trial: 12217418
Drug: Nociceptin (200pmol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nociceptin (200pmol) administered into tender non-dominant trapezius muscles
Trial: 12217418
Drug: Nociceptin administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nociceptin administered into temporal muscle (open labeled design)
Trial: 10731128
Drug: UVB phototherapy
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: UVB phototherapy plus vehicle gel
Trial: 8749244
Drug: Sumatriptan 6
RxNorm normalized name: sumatriptan 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan 6 mg subcutaneously
Trial: 8749244
Drug: Sumatriptan 12
RxNorm normalized name: sumatriptan 12 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan 12 mg subcutaneously
Trial: 19444560
Drug: Lidocaine 1.5
RxNorm normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1.5 mg x kg(‐1) i.v. bolus 30 min before induction, followed by an infusion of 1.5 mg x kg(‐1) x h(‐1) until 1 h after surgery (n = 45)
Trial: 17679315
Drug: Vagus nerve
RxNorm normalized name: SUS SCROFA VAGUS NERVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vagus nerve stimulation (VNS), details on dosage and duration not specified
Trial: 12465163
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of supervised exercise program and group education
Trial: 8126497
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (total lymphoid irradiation, TLI)
Trial: 8126497
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (TLI)
Trial: 30657995
Drug: MIRT (Multidisciplinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIRT (Multidisciplinary Intensive Rehabilitation Treatment)
Trial: 30657995
Drug: MIRT-AT (MIRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIRT-AT (MIRT with Aquatic Therapy)
Trial: 26018633
Drug: Early invitation
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early invitation to food supplementation combined with multiple micronutrient supplements (MMS) including 30 mg iron and 400 μgm folic acid.
Trial: 26018633
Drug: Usual invitation
RxNorm normalized name: BERGAMOT,IMITATION
DrugBank: Bergamot oil (DB14335)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual invitation to food supplementation combined with 60 mg iron and 400 μgm folic acid (UFe60F).
Trial: 24334857
Drug: Autologous high‐molecular‐weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous high‐molecular‐weight plasma protein fraction therapy (AHPT)
Trial: 24334857
Drug: Autologous plasma
RxNorm normalized name: AUTOLOGOUS CONDITIONED PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous plasma therapy (APT)
Trial: 23102619
Drug: Resveratrol supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol supplementation (75 mg/day for 12 weeks)
Trial: 17916183
Drug: Tadalafil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (20 mg/every other day)
Trial: 11952923
Drug: Group musical
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group musical therapy (15 sessions over 4 months)
Trial: 11952923
Drug: Group musical
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group musical therapy
Trial: 2354476
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (no thrombolytic therapy)
Trial: 391176
Drug: Mepartricin (SPA‐S‐160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepartricin (SPA‐S‐160 enteric‐coated tablets)
Trial: 27258938
Drug: Eugluc‐Hiinsu clamp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eugluc‐Hiinsu clamp with GIP infusion (1.5 pmol/kg/min)
Trial: 27258938
Drug: Hyperglycemic‐hyperinsulinemic clamp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycemic‐hyperinsulinemic clamp with GIP infusion (1.5 pmol/kg/min)
Trial: 25024629
Drug: I.31 high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.31 high dose (n = 28)
Trial: 25024629
Drug: I.31 low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.31 low dose (n = 27)
Trial: 25024629
Drug: I.31 high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.31 high dose
Trial: 25024629
Drug: I.31 low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.31 low dose
Trial: 22050270
Drug: Half-body fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-body fractional CO(2) laser therapy followed by NB‐UVB phototherapy
Trial: 20920436
Drug: Inhaled FDKP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled FDKP (20 mg) in DNP subjects
Trial: 20920436
Drug: Inhaled FDKP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled FDKP (20 mg) in subjects with normal renal function
Trial: 20920436
Drug: Inhaled FDKP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled FDKP (20 mg) in healthy subjects
Trial: 20920436
Drug: Inhaled FDKP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled FDKP (20 mg) in CLD subjects
Trial: 20920436
Drug: Intravenous FDKP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous FDKP
Trial: 20920436
Drug: Oral FDKP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral FDKP
Trial: 8751847
Drug: Catheter-based radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheter-based radiation therapies
Trial: 25786369
Drug: AMG 416
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 416 (10 mg)
Trial: 25786369
Drug: AMG 416
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 416 (5 mg)
Trial: 22054204
Drug: MEL 308
RxNorm normalized name: Mel
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEL 308 nm + oral vitamin E
Trial: 22054204
Drug: MEL 308
RxNorm normalized name: Mel
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEL 308 nm + 0.1% tacrolimus + oral vitamin E
Trial: 22054204
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin E
Trial: 19602250
Drug: Active acupuncture
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active acupuncture treatment (real acupuncture), 3 times per week for 12 sessions over 4 weeks.
Trial: 19602250
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture treatment, 3 times per week for 12 sessions over 4 weeks.
Trial: 19602250
Drug: Waitlist control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlist control group, no treatment during the 4 weeks, only recording symptoms in a daily diary.
Trial: 17496402
Drug: Antibiotic lock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic lock therapy using vancomycin and gentamycin
Trial: 11907931
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) - transdermal estradiol 50 micrograms/day and 5 mg medroxyprogesterone acetate (MPA) for 2 years
Trial: 7815242
Drug: High dosing
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dosing (1,500 U lipase/kg body weight/meal, 750 U lipase/kg body weight/snack)
Trial: 7815242
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing (500 U lipase/kg body weight/meal, 250 U lipase/kg body weight/snack)
Trial: 7815242
Drug: High dosing
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dosing in Group 1 (n = 7)
Trial: 7815242
Drug: High dosing
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dosing in Group 2 (n = 14)
Trial: 2900252
Drug: Bethanechol (5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bethanechol (5.0 mg s.c.)
Trial: 2900252
Drug: Atropine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (1.0 mg i.v.)
Trial: 31197369
Drug: Neuromuscular electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neuromuscular electrical stimulation (NMES) treatment sessions for quadriceps muscles over 16 weeks (36 sessions)
Trial: 23218533
Drug: Sublingual Zolpidem
RxNorm normalized name: zolpidem Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual Zolpidem 10mg
Trial: 23218533
Drug: Sublingual Zolpidem
RxNorm normalized name: zolpidem Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual Zolpidem 5mg
Trial: 23218533
Drug: Oral Zolpidem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Zolpidem 10mg
Trial: 16574034
Drug: Transdermal buprenorphine
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Transdermal buprenorphine (TDB) 35 mug/h patch
Trial: 16574034
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl (DDTDF) 25 mug/h patch
Trial: 1793781
Drug: Cisapride 30
RxNorm normalized name: cisapride 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 30 mg t.d.s., by rectal administration
Trial: 20491142
Drug: HyperHAES solution
RxNorm normalized name: Hyperhep B Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HyperHAES solution (7.2% sodium chloride and hydroxyethyl starch 200/0.5)
Trial: 20491142
Drug: 15% mannitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% mannitol solution
Trial: 20491142
Drug: 10% sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% sodium chloride solution
Trial: 17340596
Drug: Caries preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caries preventive agent
Trial: 11719739
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (2 g) plus intravenous metoclopramide (20 mg)
Trial: 11719739
Drug: Intravenous metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoclopramide (20 mg) plus placebo (intravenous saline solution)
Trial: 11719739
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate plus metoclopramide
Trial: 9167373
Drug: buprenorphine 0.2
RxNorm normalized name: buprenorphine 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buprenorphine 0.2 mg sublingually two hours before dilatation
Trial: 9167373
Drug: pentazocine 30
RxNorm normalized name: pentazocine 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pentazocine 30 mg intravenously five minutes before dilatation
Trial: 7701413
Drug: Rehabilitative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitative therapy (FKT)
Trial: 7701413
Drug: FKT and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FKT and Ditropan (1 tablet 3 times daily for weeks therapy)
Trial: 7701413
Drug: Traditional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional therapy with electric functional stimulation (SEF)
Trial: 3295180
Drug: Fenoterol depot
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol depot (21 mg, single dose, p.o.)
Trial: 3295180
Drug: Fenoterol (22.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (22.5 mg, three doses, p.o.)
Trial: 11062355
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg alendronate
Trial: 1313762
Drug: 15 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g/day rice bran
Trial: 3019810
Drug: 15 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g/day wheat bran
Trial: 1313762
Drug: 30 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g/day rice bran
Trial: 1313762
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g wheat bran
Trial: 1313762
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g rice bran
Trial: 3933199
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg nightly for 3 years
Trial: 8791968
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg nightly
Trial: 30020088
Drug: Pregabalin 75
RxNorm normalized name: pregabalin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 75 mg orally 1 hour before surgery and at postoperative 12th and 24th hours
Trial: 30020088
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg orally 1 hour before surgery, placebo at postoperative 12th hour, and duloxetine 60 mg at 24th hour
Trial: 30020088
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules orally at all timepoints
Trial: 22155172
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg rifaximin-EIR, given twice daily for 12 weeks
Trial: 22155172
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg rifaximin-EIR, given twice daily for 12 weeks
Trial: 22155172
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg rifaximin-EIR, given twice daily for 12 weeks
Trial: 16288372
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of IPV
Trial: 10609245
Drug: Intraoperative injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative injection of epinephrine 1:25,000 in the anterior chamber
Trial: 7718375
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose isoflurane
Trial: 2248029
Drug: tiaprofenic acid
RxNorm normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiaprofenic acid 300 mg, twice a day for seven consecutive days
Trial: 2248029
Drug: placebo, twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, twice a day for seven consecutive days
Trial: 7221983
Drug: Corynebacterium parvum
RxNorm normalized name: Corynebacterium parvum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corynebacterium parvum (7 mg)
Trial: 7221983
Drug: Mustine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mustine (20 mg)
Trial: 29688123
Drug: Early endovenous
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early endovenous ablation of superficial venous reflux with compression therapy
Trial: 29688123
Drug: Deferred endovenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred endovenous ablation of superficial venous reflux with compression therapy
Trial: 28351379
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (1 mg/kg) for 3 days
Trial: 28351379
Drug: Partial endodontic
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial endodontic treatment
Trial: 25581605
Drug: Routine incontinence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine incontinence care plus the suspension positioning system (SPS)
Trial: 21110172
Drug: Composite sophora
RxNorm normalized name: Sophora pachycarpa whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite sophora colon-soluble capsules (CSCC) high dose (six capsules, thrice a day)
Trial: 21110172
Drug: Composite sophora
RxNorm normalized name: Sophora pachycarpa whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite sophora colon-soluble capsules (CSCC) low dose (four capsules, thrice a day)
Trial: 21110172
Drug: Mesalazine Enteric-coated
RxNorm normalized name: mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalazine Enteric-coated Tablets (four tablets, thrice a day)
Trial: 21110172
Drug: Composite sophora
RxNorm normalized name: Sophora pachycarpa whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite sophora colon-soluble capsules (CSCC) high dose
Trial: 21110172
Drug: Composite sophora
RxNorm normalized name: Sophora pachycarpa whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite sophora colon-soluble capsules (CSCC) low dose
Trial: 21110172
Drug: Mesalazine Enteric-coated
RxNorm normalized name: mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalazine Enteric-coated Tablets
Trial: 11965231
Drug: Radioimmunoconjugates emitting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioimmunoconjugates emitting beta-particles (e.g., 131I-anti-CD33, 90Y-anti-CD33, 131I-anti-CD45, 188Re-anti-CD66c)
Trial: 11965231
Drug: Radioimmunoconjugates emitting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioimmunoconjugates emitting alpha-particles (e.g., 213Bi-anti-CD33)